Device Trial Radar · NCT03003806
Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study
Last checked: Nov 19, 2026Latest source record: Dec 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Oct 2, 2017
Primary completion
Nov 10, 2019
Study completion Nov 10, 2019
Sponsor
- Lead sponsor
- Rabin Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- DreaMed; The Leona M. and Harry B. Helmsley Charitable Trust
- First posted
- Dec 28, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 10 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DreaMed Advisor Pro is a software which automatically analyses treatment information, learns patient's needs and accordingly suggests adjustments in insulin dosing. The DreaMed Advisor Pro uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests pump-setting changes for optimization of glucose control The algorithm is designed as an advisory tool and has three main components: 1. A statistical analysis of the insulin pump and sensor data: insulin delivery, bolus-calculator rate of use, sensor glucose variables, hypoglycemic and hyperglycemia patterns. 2. Practical recommendations, alert messages based on aforementioned data 3. Recommendation for new insulin pump settings: including basal intervals and rate, different carbohydrate ratio according to time of day, correction factor and insulin sensitivity time. The main goal of the DreaMed Advisor Pro is to improve diabetes management for subjects with Type 1 Diabetes (T1D) by using an innovative Advisor to determine insulin dosing for pump users. The main objective of the proposed study is to evaluate the safety and efficacy of using the DreaMed Advisor Pro algorithm versus medical guided recommendation to determine insulin dosing for sub-optimal controlled subjects with type 1 diabetes using pump therapy.
Conditions
- Type1 Diabetes Mellitus
Interventions
DreaMed Advisor ProDevice
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
Medical guided recommendationOther
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of glucose readings within range of 70-180 mg/dl (3.9 to 10 mmol/l).Time frame: Final visit (week 31)
- Percentage of glucose readings below 54 mg/dl (3.3 mmol/l)Time frame: Final visit (week 31)
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Barbara Davis Center for Childhood Diabetes
Aurora, Colorado
Yale University School of Medicine
New Haven, Connecticut
University of Florida College of Medicine
Gainesville, Florida
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.